🔗 Share this article

As America proceeds with sweeping changes to its vaccination recommendations, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning Covid vaccines during the global health crisis and has zeroed in on alleged deaths following Covid immunization in her recent tenure at the FDA.

Planned Overhauls to Pediatric Immunization Program

Public health authorities planned to reveal sweeping changes to the pediatric vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a substantial departure that would put the US out of step with a large portion of the global community with no evidence for public health gain. The announcement has been postponed until the coming year.

Instead of the top vaccines chief, Høeg is listed to present at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric immunization guidelines in the US so as to align more like the Danish model, a nation with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

To date statements, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Background

Høeg has no apparent track record in medication creation, oversight or leadership, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an immense range of responsibilities at the agency, she emphasized.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one must be supervised,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a major leadership component to the role, which manages in excess of 5,000 personnel. “It is a huge management job, if you do it right,” the former official said.

Agency Reaction and Contentious Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this selection indicates increased cooperation among agency officials on vaccines, a representative responded that the “questions stem from incorrect premises”.

“This background is consistent with the duties of her position,” the official said, noting the time Høeg spent counseling the agency head on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a disputed one-day medication authorization process that apparently troubled her predecessors. “By what process are these drugs being selected for this fast-track system? Who makes the choices?” Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards laxer rules of most medications, with the exception of shots.”

Documented Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, history, critics have noted. She authored a analysis using unverified crowd-sourced reports to determine the incidence of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming government encompassed changing guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a podcast. At the FDA, Høeg has according to sources suggested excluding adolescent males from getting COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her beliefs and reverse-engineers to accommodate the data in a very misleading, dishonest manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|